During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck's dividend is well-covered, and shares are positioned for appreciation, making current pricing an attractive entry point. Last month, the FDA's Oncologic Drugs Advisory Committee voted 10-2 ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

“But in this case, I think from a scientific point of view in ... a federal judge in West Virginia last year ruled that Mylan ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

He was a postdoctoral fellow at Harvard University from 1985-88 and then joined Merck Research Laboratories at West Point, Pennsylvania, as a medicinal chemist. In 1994, he became an assistant ...

GME's fate isn't likely to be sealed in the next 12 months, Pachter adds, "but we expect the company's demise at some point later this decade." Looking ahead, Thursday's economic calendar features ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064 ...

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an antibody-drug ...